Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model-Reference-Cited by-同舟云学术

Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model

Published:2022-05-06 Issue:12 Volume:71 Page:2943-2955
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Varghese Bindu,Lynch Lydia,Vriend Lianne E.,Draganov Dobrin,Clark Justice M.,Kissick Haydn T.,Varghese Sharlin,Sanda Martin G.,Dranoff Glenn,Arredouani M. Simo,Balk Steven P.^ORCID,Exley Mark A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-022-03210-8.pdf

Reference52 articles.

1. Porcelli S, Yockey CE, Brenner MB, Balk SP (1993) Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 178:1–16

2. Brennan PJ, Brigl M, Brenner MB (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 13:101–117. https://doi.org/10.1038/nri3369

3. Mori L, Lepore M, De Libero G (2016) The Immunology of CD1- and MR1-restricted T cells. Annu Rev Immunol 34:479–510. https://doi.org/10.1146/annurev-immunol-032414-112008

4. Exley MA, Dellabona P, Casorati G (2021) Exploiting CD1-restricted T cells for clinical benefit. Mol Immunol 132:126–131. https://doi.org/10.1016/j.molimm.2020.12.015

5. Carreno LJ, Kharkwal SS, Porcelli SA (2014) Optimizing NKT cell ligands as vaccine adjuvants. Immunotherapy 6:309–320. https://doi.org/10.2217/imt.13.175

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cytokine and chemokine signaling pathways for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-22

2. Mucosal-associated invariant T cells in hematological malignancies: Current knowledge, pending questions;Frontiers in Immunology;2023-03-20